• Kenalog (Triamcinolone) 4mg 50 tablets

Expiration date: 03/2026

Dosage form

Pills

Composition

The active substance - triamcinolone.

Packaging

50 PCs

Pharmacological action

KENALOG - GCS, inhibits the release of interleukin - 1, 2, and interferon-gamma from lymphocytes and macrophages. Induces the formation lipokortinov inhibits the release of eosinophils mediators of inflammation, reduces and stabilizes the membranes of fat cells. Anti-inflammatory, antiallergic, antiedemic, anti-proliferative and immunosuppressive effect. Reduces bronchial hyperreactivity, restores the sensitivity of receptors to beta-agonists. Stabilizes the membranes of fat cells, inhibits the activity of phospholipase A2, decreases the release of arachidonic acid from the phospholipids of cell membranes and the formation of products of its metabolism (Pg, TX, leukotrienes). Antiallergic effect develops as a result of the suppression of synthesis and secretion of mediators of Allergy brake release from sensitized tocuh cells and basophils of histamine and. biologically active substances, reduction of circulating basophils, inhibition of development of lymphoid and connective tissue, reducing the number of T - and b-lymphocytes, mast cells, reducing the sensitivity of effector cells to the mediators of allergies, inhibition of antibody productions, changes the immune response of the body. Antishock and toxic effect associated with increased blood pressure (by increasing the concentration of circulating catecholamines and restoration of sensitivity to them of adrenergic receptors and vasoconstriction), decrease vascular permeability, membraneprotective properties, activation of liver enzymes involved in the metabolism of endo - and xenobiotics. Suppresses the release of pituitary ACTH and beta-lipotropina, but does not reduce the level of circulating beta-endorphin. It inhibits secretion of TSH and FSH. Increases the excitability of the Central nervous system, reduces the number of lymphocytes and eosinophils, increases &,-, erythrocytes (stimulates the production of erythropoietin). Has a pronounced dose-dependent effect on the metabolism of carbohydrates, proteins and fats. Increases glycogenes, increases fat breakdown, delays of the PA+ and water promotes the excretion of K+, reduces the absorption of Ca2+, induces the secretion of parathyroid hormone, mobilizing Ca2+ from bone tissue. Activates katabolicescie processes. For anti-inflammatory activity of triamcinolone is close to hydrocortisone, triamcinolone acetonide in 6 times more active. Mineralocorticoid activity is practically nonexistent. After the/m introduction the maximum effect is observed after 24-48 h, the duration of the on/m introduction &, - a, 1-6 weeks, in the joint cavity &,ndash several weeks.

Testimony

Adrenal insufficiency, autoimmune thyroiditis, hypercalcemia of malignancy, psoriatic arthritis, gouty and rheumatoid arthritis (including juvenile), ankylosing spondylitis, bursitis, tenosynovitis, post-traumatic osteoarthritis, epicondylitis, systemic lupus erythematosus, rheumatic heart disease, pemphigus, syndrome of Stevens - Johnson, erythema multiforme, dermatitis (exfoliative, herpetiformis, bullous, seborrheic, contact, atopic), psoriasis, allergic rhinitis, bronchial asthma, serum or drug-disease, allergic conjunctivitis, keratitis, iridocyclitis, sarcoidosis, Leffler syndrome, Lyme disease, aspiration pneumonia, idiopathic thrombocytopenic purpura adults, secondary thrombocytopenia in adults, anemia (autoimmune hemolytic, hereditary hypoplastic), eritroblastopenia, acute or chronic lymphoblastic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, breast cancer, prostate cancer, multiple myeloma, tubercular meningitis, acute lymphocytic leukemia in children, nephrotic syndrome, ulcerative colitis, Crohn's disease, celiac disease, hyperthermia in malignant tumors.

Contraindications

Hypersensitivity, systemic fungal infections, osteoporosis, glaucoma, peptic ulcer and duodenal ulcer, renal failure, acute viral and bacterial infections, pregnancy, lactation, children up to age six years.

Method of application and doses

Inside adult - 4-20 mg per day in 2-3 reception. After improving the daily dose gradually reduced to 1-2 mg every 2-3 days to a minimum maintenance dose of 1 mg and a complete discontinuation of therapy.

Side effects

Insomnia, anxiety, withdrawal syndrome (adrenal insufficiency), secondary immunodeficiency (exacerbation of chronic infectious diseases, infectious generalization process, the development of opportunistic infections), slowing of reparative processes, steroid diabetes mellitus, syndrome, start with those - Cushing's, hypertension, myocardial dystrophy, cardiac arrhythmia, swelling, muscle weakness, muscle atrophy, osteoporosis, multiple caries, spontaneous fractures, growth retardation in children, steroid stomach ulcers, intestinal atony, the propensity to thrombosis, skin atrophy at the site of application, hypertrichosis, stretch marks, folliculitis, maceration or dryness of the skin, allergic reactions.

Interaction

Intensifies the side effects of NSAIDs, cytostatics and immunosuppressants. Reduces the effectiveness of oral hypoglycemic agents, insulin, antihypertensive and diuretics, growth hormone. In combination with viral vaccines promotes replication of virus particles and/or decrease antibody production.

Kenalog
(Triamcinolone)
4mg
50
tablets